Multiple sclerosis (MS) is a common, chronic neurological disease with a highly variable prognosis and clinical course. There is a pressing need for reliable predictors of future disease course not only for individual patient counseling, but also because there are now disease-modifying treatments that favorably modify the early relapsing-remitting phase of the disease. And it is desirable to know for whom such treatments are most needed and useful.
↧
